Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI

Sarah Jane Schwarzenberg,Phuong T. Vu, Michelle Skalland,Lucas R. Hoffman,Christopher Pope,Daniel Gelfond,Michael R. Narkewicz,David P. Nichols,Sonya L. Heltshe,Scott H. Donaldson, Carla A. Frederick,Andrea Kelly,Jessica E. Pittman,Felix Ratjen,Margaret Rosenfeld,Scott D. Sagel,George M. Solomon,Michael S. Stalvey,John P. Clancy,Steven M. Rowe

Journal of Cystic Fibrosis（2023）

引用 20|浏览23

暂无评分

摘要

•After 6 months of ETI there is modest improvement in gastrointestinal symptoms in people with CF.•ETI reduces markers of intestinal inflammation after 6 months.•In CF >12 years of age, there was no improvement in fecal elastase after 6 months of ETI.

查看译文

关键词

Modulators,Patient-reported outcomes measures,Inflammation,Pancreatic insufficiency

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要